Drug Discovery & DDS– category –
-
Chemoenzymatic Ligation Offers Scalable Solution to Nucleic Acid Therapeutics Manufacturing Bottlenecks, Surpassing Solid-Phase Synthesis Limits
The Medicine Maker Unknown Overview A new chemoenzymatic ligation technology is emerging as a scalable solution to the manufacturing bottlenecks in nucleic acid therapeutics, such as siRNA and mRNA. This approach efficiently assembles ol... -
Widespread GLP-1 Agonist Use Reduces US Adult Obesity Rate by 2% (2022-2025); WHO Recognizes Obesity as Chronic Disease
LinkedIn USA Overview Widespread adoption of GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound) has correlated with a 2% reduction in the US adult obesity rate between 2022 and 2025. This impact is reinforced by ongoing Phase ... -
Viking Therapeutics Initiates Phase 2 VENTURE-Oral Trial for Oral Dual GLP-1/GIP Agonist VK2735 in Obesity
Superpower USA Overview Viking Therapeutics has commenced its Phase 2 VENTURE-Oral trial in early 2025 for VK2735, an oral dual GLP-1/GIP receptor agonist targeting obesity. This move highlights the intense competition in the metabolic d... -
CDMO Curia Massively Expands Sterile Fill-Finish Capacity in UK, US for Biologics and ADCs
Packaging Digest UK, USA Overview CDMO Curia has significantly expanded its sterile fill-finish manufacturing facilities in Glasgow, UK, and Albuquerque, US, to meet surging demand for biologics and highly potent antibody-drug conjugates... -
Drug Discovery & DDS Weekly Report August 30, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 30, 2026 (PDF) — Download Weekly Report August 30, 2026 (PDF) — DownloadDownload 🎙 Podcast August 30, ... -
WuXi XDC Reports $550.4M H1 Revenue (37% YoY Growth) and Reaffirms $1.2B Investment in ADC Manufacturing Capacity by 2030
Fierce Biotech China Overview WuXi XDC, the ADC-focused subsidiary of WuXi Bio, reported a significant 37% year-over-year revenue increase to RMB 3.7 billion (approximately $550.4 million) in the first half of 2026. The company also reaf... -
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib) as First Broad RAS-Targeted Medicine for Metastatic Pancreatic Cancer
MarketScreener USA Overview Revolution Medicines announced that its RASONQUE™ (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer, has received U.S. FDA approval. RASONQUE had previously been granted Br... -
U.S. FDA Approves Pfizer and BioNTech’s XFG-Adapted COVID-19 Vaccine, Aligned with 2026 Fall Vaccination Guidance
Pfizer USA Overview Pfizer and BioNTech have received U.S. FDA approval for their XFG-adapted COVID-19 vaccine. This approval aligns with the FDA's guidance on the recommended composition for COVID-19 vaccines to be used in the United St... -
AI Firm Noetik Achieves First Milestone in GSK Collaboration, Deploying OCTO-VC Foundational Model’s Inference and Fine-tuning Capabilities for Oncology Drug Discovery
Business Wire Global Overview AI company Noetik has successfully achieved its first short-term milestone in a five-year strategic collaboration and licensing agreement with GSK. This accomplishment was met by Noetik's delivery and deploy... -
Samsung Biologics Announces KRW 3 Trillion ($2.18B) Rights Offering to Fund PolyPeptide Group Acquisition and Bio Campus II Expansion, Strengthening CDMO Leadership
PR Newswire South Korea Overview Samsung Biologics has announced a substantial KRW 3 trillion (approximately $2.18 billion) rights offering to finance its acquisition of PolyPeptide Group and the expansion of its Bio Campus II. This stra...
